A carregar...
Requiring an amyloid-β(1-42) biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials
BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-β(1-42) concentration and high total-tau/Aβ(1-42) ratio have been recommended to support the diagnosis of prodromal Alzheimer’s disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and also to select patients for clinical trials. M...
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2947209/ https://ncbi.nlm.nih.gov/pubmed/20813339 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2010.07.004 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|